Last reviewed · How we verify

CoronaVac Vaccine — Competitive Intelligence Brief

CoronaVac Vaccine (CoronaVac Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine. Area: Immunology / Infectious Disease.

phase 3 Inactivated viral vaccine SARS-CoV-2 spike protein and other viral antigens Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

CoronaVac Vaccine (CoronaVac Vaccine) — Clover Biopharmaceuticals AUS Pty. CoronaVac is an inactivated SARS-CoV-2 vaccine that stimulates the immune system to produce antibodies and cellular immunity against the virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CoronaVac Vaccine TARGET CoronaVac Vaccine Clover Biopharmaceuticals AUS Pty phase 3 Inactivated viral vaccine SARS-CoV-2 spike protein and other viral antigens
COVAX only (1st and 2nd dose) COVAX only (1st and 2nd dose) China National Biotec Group Company Limited marketed Inactivated viral vaccine SARS-CoV-2 spike protein and other viral antigens
CCP CCP Metro Infectious Disease Consultants marketed Convalescent plasma SARS-CoV-2 spike protein and other viral antigens
Inactivated SARS-CoV-2 Vaccine (Vero cell) Inactivated SARS-CoV-2 Vaccine (Vero cell) Sinovac Research and Development Co., Ltd. marketed inactivated viral vaccine SARS-CoV-2 spike protein and other viral antigens
Inactivated SARS-CoV-2 vaccine Inactivated SARS-CoV-2 vaccine Jiangsu Province Centers for Disease Control and Prevention phase 3 Inactivated viral vaccine SARS-CoV-2 spike protein and other viral antigens
CoronaVac/CoronaVac CoronaVac/CoronaVac Institut Pasteur de Tunis phase 3 Inactivated viral vaccine SARS-CoV-2 spike protein and other viral antigens
Sinopharm BIBP Sinopharm BIBP Vaxxinity, Inc. phase 3 Inactivated viral vaccine SARS-CoV-2 spike protein and other viral antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine class)

  1. Sinovac Biotech Co., Ltd · 9 drugs in this class
  2. Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
  3. GlaxoSmithKline · 5 drugs in this class
  4. Valneva Austria GmbH · 4 drugs in this class
  5. Medical University of Vienna · 3 drugs in this class
  6. Centers for Disease Control and Prevention · 3 drugs in this class
  7. China National Biotec Group Company Limited · 2 drugs in this class
  8. Statens Serum Institut · 2 drugs in this class
  9. Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 drugs in this class
  10. Crucell Holland BV · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CoronaVac Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/coronavac-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: